Outlook Therapeutics (OTLK) Net Equity Issued and Repurchased (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Net Equity Issued and Repurchased for 11 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 387.08% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $32.0 million (up 335.61% YoY), while the FY2025 annual figure was $25.4 million, down 57.91% from the prior year.
• Net Equity Issued and Repurchased slipped to $6.9 million in Q1 2026 per OTLK's latest filing, from $14.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $24.6 million in Q4 2022 and bottomed at -$114954.0 in Q3 2024.
• Historically, Net Equity Issued and Repurchased has averaged $5.0 million across 5 years, with a median of $2.4 million in 2023.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased slumped 104.74% — and 2025, when it soared 7133.26%.
• Outlook Therapeutics' Net Equity Issued and Repurchased stood at $24.6 million in 2022, then tumbled by 90.15% to $2.4 million in 2023, then decreased by 28.22% to $1.7 million in 2024, then jumped by 756.97% to $14.9 million in 2025, then sank by 53.8% to $6.9 million in 2026.
• Business Quant data shows OTLK's Net Equity Issued and Repurchased at $6.9 million in Q1 2026, $14.9 million in Q4 2025, and $8.1 million in Q3 2025.